File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.addr.2020.10.018
- Scopus: eid_2-s2.0-85096237982
- PMID: 33137363
- WOS: WOS:000600556400014
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic
Title | Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic |
---|---|
Authors | |
Keywords | Benzodiazepine Buccal End-of-life drug Intranasal Opioid |
Issue Date | 2020 |
Publisher | Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/addr |
Citation | Advanced Drug Delivery Reviews, 2020, v. 160, p. 234-243 How to Cite? |
Abstract | The Coronavirus disease 2019 (COVID-19) pandemic has led to a surge in need for alternative routes of administration of drugs for end of life and palliative care, particularly in community settings. Transmucosal routes include intranasal, buccal, sublingual and rectal. They are non-invasive routes for systemic drug delivery with the possibility of self-administration, or administration by family caregivers. In addition, their ability to offer rapid onset of action with reduced first-pass metabolism make them suitable for use in palliative and end-of-life care to provide fast relief of symptoms. This is particularly important in COVID-19, as patients can deteriorate rapidly. Despite the advantages, these routes of administration face challenges including a relatively small surface area for effective drug absorption, small volume of fluid for drug dissolution and the presence of a mucus barrier, thereby limiting the number of drugs that are suitable to be delivered through the transmucosal route. In this review, the merits, challenges and limitations of each of these transmucosal routes are discussed. The goals are to provide insights into using transmucosal drug delivery to bring about the best possible symptom management for patients at the end of life, and to inspire scientists to develop new delivery systems to provide effective symptom management for this group of patients. |
Persistent Identifier | http://hdl.handle.net/10722/293408 |
ISSN | 2023 Impact Factor: 15.2 2023 SCImago Journal Rankings: 3.411 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lam, JKW | - |
dc.contributor.author | Cheung, CCK | - |
dc.contributor.author | Chow, MYT | - |
dc.contributor.author | Harrop, E | - |
dc.contributor.author | Lapwood, S | - |
dc.contributor.author | Barclay, SIG | - |
dc.contributor.author | Wong, ICK | - |
dc.date.accessioned | 2020-11-23T08:16:19Z | - |
dc.date.available | 2020-11-23T08:16:19Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Advanced Drug Delivery Reviews, 2020, v. 160, p. 234-243 | - |
dc.identifier.issn | 0169-409X | - |
dc.identifier.uri | http://hdl.handle.net/10722/293408 | - |
dc.description.abstract | The Coronavirus disease 2019 (COVID-19) pandemic has led to a surge in need for alternative routes of administration of drugs for end of life and palliative care, particularly in community settings. Transmucosal routes include intranasal, buccal, sublingual and rectal. They are non-invasive routes for systemic drug delivery with the possibility of self-administration, or administration by family caregivers. In addition, their ability to offer rapid onset of action with reduced first-pass metabolism make them suitable for use in palliative and end-of-life care to provide fast relief of symptoms. This is particularly important in COVID-19, as patients can deteriorate rapidly. Despite the advantages, these routes of administration face challenges including a relatively small surface area for effective drug absorption, small volume of fluid for drug dissolution and the presence of a mucus barrier, thereby limiting the number of drugs that are suitable to be delivered through the transmucosal route. In this review, the merits, challenges and limitations of each of these transmucosal routes are discussed. The goals are to provide insights into using transmucosal drug delivery to bring about the best possible symptom management for patients at the end of life, and to inspire scientists to develop new delivery systems to provide effective symptom management for this group of patients. | - |
dc.language | eng | - |
dc.publisher | Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/addr | - |
dc.relation.ispartof | Advanced Drug Delivery Reviews | - |
dc.subject | Benzodiazepine | - |
dc.subject | Buccal | - |
dc.subject | End-of-life drug | - |
dc.subject | Intranasal | - |
dc.subject | Opioid | - |
dc.title | Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic | - |
dc.type | Article | - |
dc.identifier.email | Lam, JKW: jkwlam@hku.hk | - |
dc.identifier.email | Chow, MYT: mytchow@hku.hk | - |
dc.identifier.email | Wong, ICK: wongick@hku.hk | - |
dc.identifier.authority | Lam, JKW=rp01346 | - |
dc.identifier.authority | Wong, ICK=rp01480 | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1016/j.addr.2020.10.018 | - |
dc.identifier.pmid | 33137363 | - |
dc.identifier.pmcid | PMC7603972 | - |
dc.identifier.scopus | eid_2-s2.0-85096237982 | - |
dc.identifier.hkuros | 318753 | - |
dc.identifier.volume | 160 | - |
dc.identifier.spage | 234 | - |
dc.identifier.epage | 243 | - |
dc.identifier.isi | WOS:000600556400014 | - |
dc.publisher.place | Netherlands | - |
dc.identifier.issnl | 0169-409X | - |